InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Orphan Drug Designation for NV-387
NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles, providing potential incentives including tax credits, fee exemptions and market exclusivity. The company said the designation supports regulatory advancement of NV-387, a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to…